DXS International plc Trading Statement
17 Mayo 2023 - 6:14AM
UK Regulatory
TIDMDXSP
DXS INTERNATIONAL PLC
(AQSE: DXSP)
Trading Update -- May 2023
DXS International plc ("DXS" or the "Company"), the digital
clinical decision support company, is pleased to provide
shareholders with a trading update.
The company expects revenue for the year ending April 2023 to be
GBP3.3 million, marginally up on April 2022, with a very small
profit after tax.
With the NHS largely inaccessible from a sales and marketing
perspective, the company has during the past three years used this
time to pilot new sophisticated SaaS solutions. Based on feedback
from the various pilots, the company has enhanced the solutions,
gained additional NHS IM1 accreditation, attained MHRA
certification (required for software classed as medical devices)
and planned the sales and marketing strategy for the financial year
ahead.
As the NHS recovery kicks in, the company has - as announced
earlier today - raised GBP500,000 at a price of 4 pence per share
through Hybridan LLP acting as sole broker, to be used mainly for
immediate sales and marketing initiatives, and to continue to drive
revenue growth and profitability. These initiatives will focus
on:
-- Leveraging off our existing 2,000 GP practices user base.
-- Targeting new greenfield prospects with convertible free trial offers.
These initiatives will build on our current two key solutions,
one existing with new SMART referral ability and the other our new
Hypertension solution. With both these solutions demonstrating
powerful Return on Investment (ROI) to both healthcare clinicians
and the NHS, these sales initiatives are underpinned by compelling
and measurable ROI.
In the next 11 months, we have the building blocks in place to
potentially rapidly scale our annual revenue to GBP4.7m by April
2024, from GBP3.3m April 2023. We intend to achieve this via a
combination of growing existing pharmaceutical income of GBP1.5
million by 8% p.a., and increasing our existing NHS revenue by 27%
from GBP1.8m to GBP2.3m, of which we already have approximately 16%
(which represents 60% of the increase) under discussion.
We intend to supplement this with additional revenue from our
new hypertension medicine optimisation product, adding
approximately GBP130,000 of new revenue from SMART Pathways, and
generating new revenue of approximately GBP700,000 from the
ExpertCare Hypertension solution. DXS has entered into an agreement
with Deontics Limited to use its AI Technology to enable the growth
in the revenue from NHS SMART Referral and SMART Pathways.
In addition, while not expected to be revenue generating within
the next 12 months, we plan our entry into the USA. This will be
via a recent bid won by DXS to conduct a hypertension trial with
North Western Medicine in Chicago.
A copy of our latest investor presentation can be found on the
Company website.
David Immelman, CEO of DXS International plc, commented:
"I am delighted with the continued support we have received from
our shareholders, and to welcome new institutions including funds
managed by Downing LLP in this latest fundraising. We are pleased
to see sentiment changing within the NHS and to hear the positive
feedback we have received on the various trials in clinics with our
new products. Building blocks are in place to potentially rapidly
scale our annual revenue to GBP4.7m by April 2024."
The Directors of DXS International plc accept responsibility for
this announcement
The information contained within this announcement is deemed to
constitute inside information as stipulated under the retained EU
law version of the Market Abuse Regulation (EU) No. 596/2014 (the
"UK MAR") which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018. The information is disclosed in accordance
with the Company's obligations under Article 17 of the UK MAR. Upon
the publication of this announcement, this inside information is
now considered to be in the public domain.
Enquiries:
David Immelman (Chief Executive) 01252 719800
DXS International plc david@dxs-systems.com
https://www.dxs-systems.co.uk
Corporate Advisor
City & Merchant
David Papworth 020 7101 7676
Corporate Broker
Hybridan LLP
Claire Louise Noyce 020 3764 2341
Note to Editors:
About DXS
DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other
trusted NHS sources, to doctors, nurses, and pharmacists in their
workflow and during the patient consultation. This effective
clinical decision support ultimately translates to improved
healthcare outcomes delivered more cost effectively which should
significantly contribute towards the NHS achieving its projected
efficiency savings.
(END) Dow Jones Newswires
May 17, 2023 07:14 ET (11:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
DXS (AQSE:DXSP)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
DXS (AQSE:DXSP)
Gráfica de Acción Histórica
De May 2023 a May 2024